here
Neumayr, Lynne, MD

Lynne Neumayr

MD

Pediatrics, Sickle Cell Disease

Co-Director, Clinical Research in Sickle Cell Disease

Request appointment Refer a patient

Clinical Specialties

Sickle cell disease, thalassemia, statistics, grants management, iron metabolism, brain injury in rare disease and sickle cell disease, apheresis

Certifications

Board Certification
  • Pediatrics

Education

Medical School

University of California, San Diego, CA

Fellowship

Children's Hospital & Research Center, Oakland, CA

Residency

Children's Hospital & Research Center, Oakland, CA (Pediatrics)

Clinic Locations

My Work

About Me

Dr. Neumayr is the Administrative Medical Director and the Co-Director of Research in Sickle Cell Disease for the Department of Hematology/Oncology Department at UCSF Benioff Children’s Hospital Oakland (BCHO). Prior to becoming a physician, she worked as a statistician at the National Institutes of Mental Health from 1979 to 1982, a background that led to collaboration with Dr. Vichinsky for over 20 years in multicenter clinical trials, investigator-sponsored local studies, and quality outcome research sponsored by HRSA and the CDC in sickle cell disease, thalassemia and other rare diseases.Dr. Neumayr is the Administrative Medical Director and the Co-Director of Research in Sickle Cell Disease for the Department of Hematology Oncology Department at UCSF Benioff Children’s Hospital Oakland (BCHO). Prior to becoming a physician, she worked as a statistician at the National Institutes of Health from 1979 to 1982, a background that led to collaboration with Dr. Vichinsky for over 20 years in multi-center clinical trials, investigator-sponsored local studies, and quality outcome research sponsored by HRSA and the CDC in sickle cell disease, thalassemia and other rare diseases.

Dr. Neumayr plays a central role in the hematology/oncology clinical and research programs. She is responsible for the linkage between research positions, hematology/oncology programs, and multiple income streams (patient revenue, grants, contracts). Under her direction, we have been able to sustain financial stability and growth of our research infrastructure. Dr. Neumayr directly manages administrative and research staff and has helped to develop the clinical research infrastructure needed to accomplish diverse academic goals of the division. Dr. Neumayr has become a principal investigator and project leader independent of other faculty and is currently a PI on a PCORI initiative funded by the UC Regents, is Co-Investigator on the the FDA-funded trial in NBIA and a CDC funded project in Thalassemia, a Co-PI in the HRSA- funded Pediatric Sickle Cell Regional Collaborative and PI on several pharmaceutical collaborations. Despite these administrative responsibilities, as a committed clinician, she is actively involved in the clinical hemoglobinopathy and apheresis programs.

Dr. Neumayr has contributed to the development of the standard of care guidelines in sickle cell disease and published articles in peer-reviewed journals, and has been on several national and state committees.

Selected Research and Publications:

  1. Neumayr LD, Aguilar C, Earles AN, Jergesen HE, Haberkern CM, Kammen BF, Nancarrow PA, Padua E, Milet M, Stulberg BN, Williams RA, Orringer EP, Graber N, Robertson SM, Vichinsky EP. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am. 2006 Dec;88(12):2573-82.
  2. Neumayr L, Pringle S, Giles S, Quirolo KC, Paulukonis S, Vichinsky EP, Treadwell MJ. Chart Card: feasibility of a tool for improving emergency department care in sickle cell disease. J Natl Med Assoc. 2010 Nov;102(11):1017-23.
  3. Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, Boudreaux J, Neufeld EJ, Kenney K, Grant A, Thompson AA; CDC Thalassemia Investigators. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention. Transfusion. 2014 Apr;54(4):972-81. 2013 Jul 25. (Epub).
  4. Morris CR, Kuypers FA, Lavrisha L, Ansari M, Sweeters N, Stewart M, Gildengorin G, Neumayr L, Vichinsky EP. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013 Sep;98(9):1375-82.
  5. R. Scott Mackin, Philip Insel, Diana Truran, Elliott P. Vichinsky, Lynne D. Neumayr, F. Daniel Armstrong, Jeffrey I. Gold, Karen Kesler, Joseph Brewer, and Michael Weiner. Neuroimaging Abnormalities in Adults with Sickle Cell Anemia: Associations with Cognition. Neurology. 2014 Mar 11;82(10):835-41.
  6. Porter JB, Walter PB, Neumayr LD, Evans P, Bansal S, Garbowski M, Weyhmiller MG, Harmatz PR, Wood JC, Miller JL, Byrnes C, Weiss G, Seifert M, Grosse R, Grabowski D, Schmidt A, Fischer R, Nielsen P, Niemeyer C, and Vichinsky E. Mechanisms of Plasma NTBI Generation: Insights from Comparing Transfused Diamond Blackfan Anaemia with Sickle Cell and Thalassaemia Patients. Br J Haematol. 2014 Dec;167(5):692-6.
  7. Paulukonis ST, Harris WT, Coates TD, Neumayr L, Treadwell M, Vichinsky E, Feuchtbaum LB. Population-based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatr Blood Cancer. 2014 Dec;61(12):2271-6.
  8. Dowling MM, Quinn C , Ramaciotti C, Kanter J, Osunkwo I, Inusa B, Lyer R, Kwiatkovvski J, Johnson C, Rhodes MM,Owen W, Strouse JJ, , Panepinto JA, Neumayr L, Sarnaik S, Hynan LS, Plumb P, Kirkham F., Hynan, L. and the PFAST Investigators. Increased Prevalence of Potential Right-to-Left Shunting in Children with Sickle Cell Anemia and Stroke. Submitted to Blood, April 2016.
  9. Neumayr L, Vichinsky E. “Stroke recurrence in adult sickle cell patients: It is time for action!” Transfusion. 2016 May;56(5):1001-4.